Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance
and intervention for complications. We characterized the incidence of and predictors for …

Advances in hematopoietic cell transplantation (HCT) have led to an increasing number of
transplant survivors. However, long-term survival is challenged by late relapse, late …

We assessed late mortality in 1479 individuals who had survived 2 or more years after
allogeneic hematopoietic cell transplantation (HCT). Median age at HCT was 25.9 years and …

The need for long-term follow-up (LTFU) after allogeneic hematopoietic cell transplantation
(HCT) has been increasingly recognized for managing late effects such as subsequent …

The high intensity of therapy and prolonged immune suppression after hematopoietic cell
transplantation (HCT) increase the risk of long-term complications and health care needs …

Hematopoietic cell transplantation (HCT) is an important curative treatment for children with
high-risk hematologic malignancies, solid tumors, and, increasingly, nonmalignant diseases …

Autologous blood or marrow transplantation (BMT) is a curative option for several types of
childhood cancer. However, there is little information regarding the risk of late mortality. We …

Long-term survival is now an expected outcome after hematopoietic cell transplantation
(HCT). However, the burden of morbidity long-term after HCT remains unknown. We …

Advances in hematopoietic cell transplantation (HCT) technology and supportive care
techniques have led to improvements in long-term survival after HCT. Emerging indications …

Very young children undergoing hematopoietic cell transplantation (HCT) are a unique and
vulnerable population. We analyzed outcomes of 717 patients from 117 centers who …